Comprehensive evaluation of a Thorotrast patient: an overview.
For several decades, thousands of people received Thorotrast during the course of angiography and other radiologic procedures. Eventually, as the hazards of this radioactive, radiographic contrast agent became apparent, research was initiated to further evaluate its associated adverse effects. In 1988 and 1989, Charles W. Mays, together with colleagues at a variety of sites, developed a detailed protocol for the comprehensive postmortem evaluation of one subject who had been administered Thorotrast 36 y previously. This case represents the first holistic approach to the analysis of Thorotrast in a whole body, simultaneously assembling clinical and autopsy findings with dosimetric, radiochemical, autoradiographic, and molecular evaluations.
Travis
L B
LB
Epidemiology and Biostatistics Program, National Cancer Institute, National Institutes of Health, Rockville, MD 20852.
Kathren
R L
RL
Mays
D
D
Mays
C W
CW
D000368:Aged; D003287:Contrast Media / Q000009:adverse effects* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D013911:Thorium Dioxide / Q000009:adverse effects* / Q000493:pharmacokinetics; D013997:Time Factors; D014018:Tissue Distribution
D003287:Contrast Media; D013911:Thorium Dioxide